Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
E3 ubiquitin ligases regulate many dynamic cellular processes important for cancer cell survival. Together with ubiquitin-activating enzyme (E1) and ubiquitin-conjugating enzymes (E2s), E3s catalyze the ubiquitination of numerous protein substrates that are subsequently targeted to the 26S proteasome for degradation. The clinical success of the proteasome inhibitor bortezomib has encouraged the evaluation of other components of the ubiquitin proteasome system for pharmaceutical intervention. Targeting specific E3s is particularly attractive because there is the potential to selectively block the degradation of certain cellular proteins and possibly avoid unwanted effects on other proteins. The cullin-RING ubiquitin E3 ligases (CRLs) represent the largest subfamily of E3s. The requirement that CRLs be activated by NEDD8 modification on the cullin protein offers an “achilles heel” for modulating this entire subfamily. NEDD8-activating enzyme (NAE) catalyzes the first step in the NEDD8 pathway and as such controls the activity of CRLs. In this article, we describe the role of the NEDD8 pathway in activating CRLs and discuss the preclinical findings with a first-in-class NAE inhibitor that is currently in phase I clinical trials for both solid tumor and hematological malignancies. In addition, we speculate where NAE inhibitors may find clinical utility.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cullin-based E3 ligases need to be neddylated by NEDD8 in order to activate their holoenzyme ubiquitin ligase activities (Soucy et al, 2009).”
From Targeting transcription factors through an IMiD independent zinc finger domain (2025) · cites this paper as Soucy et al, 2009
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“Nutlins have been shown to reactivate the p53 pathway in cancer cell lines leading to apoptosis (38).”
BackgroundA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 4×
“Bortezomib is a peptide boronic-acid inhibitor of the proteasome approved for the treatment of multiple myeloma and relapsed mantle cell lymphoma (12, 13).”
BackgroundInfluentialKobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224 · cited 2×
“Examples of CRL substrates with important roles in cancer Cullin Substrate adaptor/receptor module Example substrate receptors Example substrates Reference CUL1 SKP1/F-box SKP2, β-TrCP, FBW7 p27, p-IκBα, β-catenin, cyclin E, c-MYC, c-JUN, mTOR (23, 24, 45–50) CUL2,5 Elongin-BC/ SOCS-box VHL HIF1α (51) CUL3 BTB domain…”
Autophagosome formation: core machinery and adaptations
Xie, Z., & Klionsky, D. J. (2007) · Nature Cell Biology · doi:10.1038/ncb1007-1102 · Cited by 2,164
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Self-citationConcepts in sumoylation: a decade on
Geiss-Friedlander, R., & Melchior, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2293 · Cited by 1,785
Modification of Proteins by Ubiquitin and Ubiquitin-Like Proteins
Kerscher, O., Felberbaum, R., & Hochstrasser, M. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010605.093503 · Cited by 1,517
Cited by
Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., & Brownell, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3321 · Cited by 563
“Inhibition of the NEDD8 pathway was recently demonstrated using the small-molecule NEDD8-activating enzyme (NAE) inhibitor, MLN4924 (REFS 112, 113) .”
MethodAdvances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Short, N. J., Konopleva, M., Kadia, T. M., Borthakur, G., Ravandi, F., DiNardo, C. D., & Daver, N. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1011 · Cited by 368
Milhollen, M. A., Traore, T., Adams-Duffy, J., Thomas, M. P., Berger, A. J., Dang, L., Dick, L. R., Garnsey, J. J., Koenig, E., Langston, S. P., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272567 · Cited by 323
Self-citationCullin-RING Ligases as Attractive Anti-cancer Targets
Zhao, Y., & Sun, Y. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990300 · Cited by 278
Zhao, Y., Xiong, X., & Sun, Y. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.029 · Cited by 272
Metadata
- Authors
- Soucy, T. A., Smith, P. G., & Rolfe, M.
- Affiliations
- Takeda Oncology (United States) (US)
- Venue
- Clinical Cancer Research
- Published
- 2009-06-15
- Volume
- 15
- Issue
- 12
- Pages
- 3912-3916
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2120380960
- Cited by
- 222
- References
- 53
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 11 · 2023: 12 · 2022: 13 · 2021: 12 · 2020: 13 · 2019: 19 · 2018: 11 · 2017: 11 · 2016: 12 · 2015: 13 · 2014: 16 · 2013: 17 · 2012: 16
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- NEDD8-activating enzyme, cullin-RING ubiquitin ligases, E3 ubiquitin ligase, ubiquitin-proteasome system, protein degradation, cancer therapy, hematologic malignancies, solid tumors
- MeSH terms
- Bortezomib, NEDD8 Protein, Antineoplastic Agents, Boronic Acids, Cyclopentanes, Humans, Neoplasms, Pyrazines, Pyrimidines, Ubiquitins, Signal Transduction, NF-kappa B, Ubiquitin-Conjugating Enzymes, Ubiquitin-Activating Enzymes, Ubiquitin-Protein Ligases, Cullin Proteins, Proteasome Endopeptidase Complex, RING Finger Domains, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-0343
- The paper
- Soucy, T. A., Smith, P. G., & Rolfe, M. (2009). Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-0343
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.